{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:44:19Z","timestamp":1758703459183,"version":"3.41.2"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Chimeric antigen receptors (CAR) T cells (CAR-T) mark a significant step towards producing safe and effective personal anticancer treatments. CAR-T strategies engineers the T cells from the patients to allow specific binding to a tumour-specific antigen. CAR-Ts are a second-wave offensive strategy to clear out remaining chemotherapy-resistant tumour cells. Though showing practical antitumor abilities in multiple haematological malignancies and solid tumour cancers, the issues of antigen escape, tumour infiltration\/penetration, and toxicity side effects limit the usage of prolonged CAR-T therapies. However, engineering immunology has exploited human stem cell-based CAR-T therapies and the development of CAR-M (macrophage) therapies to combat the disadvantages of conventional CAR-T therapies. In this review, we will highlight the challenges of CAR-T therapies and combat them with engineering immunology for cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fcell.2022.969020","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T06:37:50Z","timestamp":1665383870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Combating challenges in CAR-T cells with engineering immunology"],"prefix":"10.3389","volume":"10","author":[{"given":"Clement Yisai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie Po","family":"Ting Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohichi","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.12788\/j.cmonc.0059","article-title":"Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia","volume":"10","author":"Abraham","year":"2013","journal-title":"Community Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s1525-0016(16)37624-9","article-title":"183. Adoptive transfer of T cells genetically targeted to the MUC16 antigen eradicates established peritoneal ovarian tumors in SCID-beige mice","volume":"18","author":"Alena","year":"2010","journal-title":"Mol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/nejmoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.ccr-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1158\/1078-0432.ccr-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific chimeric antigen receptor targeting both CD19 and CD22 T cell therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2018","journal-title":"Cancer Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/1521-4141(200204)32:4<972:aid-immu972>3.0.co;2-m","article-title":"The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance","volume":"32","author":"Eagar","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CheckMate-143: The game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/jco.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2019-121967","article-title":"B cell maturation antigen-specific CAR T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"134","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","article-title":"Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer","volume":"29","author":"Hillerdal","year":"2015","journal-title":"Biodrugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/cancers11122024","article-title":"Chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"11","author":"Hosen","year":"2019","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a Bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1089\/hum.2017.080","article-title":"Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA\u2013transfected peripheral blood lymphocytes for ovarian cancer therapy","volume":"29","author":"Hung","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function.","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic Biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.ccr-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.6004\/jadpro.2019.10.8.9","article-title":"Axicabtagene ciloleucel: The first FDA-approved CAR T-cell therapy for relapsed\/refractory large B-cell lymphoma.","volume":"10","author":"King","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors.","volume":"409","author":"Klampatsa","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamaneurol.2021.0890","article-title":"Risk factors with neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Liu","year":"2021","journal-title":"JAMA Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-Targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/elife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"ELife"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/jco.2008.16.1935","article-title":"Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma","volume":"26","author":"Pantuck","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11899-017-0425-7","article-title":"Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond","volume":"12","author":"Pemmaraju","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/cells10040808","article-title":"Adoptive T cell therapy for solid tumors: Pathway to personalized standard of care","volume":"10","author":"Qin","year":"2021","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/ijms19061602","article-title":"Immunotherapy for gastric cancer: Time for a personalized approach?","volume":"19","author":"Riccardo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells hit the tumor microenvironment: Strategies to overcome tumor escape.","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.cd-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B50","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"B51","doi-asserted-by":"publisher","first-page":"788211","DOI":"10.3389\/fimmu.2021.788211","article-title":"A systematic review on PD-1 blockade and PD-1 gene-editing of CAR-T cells for glioma therapy: From deciphering to personalized medicine","volume":"12","author":"Shadbad","year":"2022","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3892\/or.2019.7263","article-title":"The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells","volume":"42","author":"Shen","year":"2019","journal-title":"Oncol. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"TPS3115","DOI":"10.1200\/jco.2013.31.15_suppl.tps3115","article-title":"Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)","volume":"31","author":"Slovin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/nejmoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-Directed CAR-T cells","volume":"28","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"E403","DOI":"10.3390\/ijms19020403","article-title":"Nanobody based dual specific CARs","volume":"19","author":"Stijn","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-94-007-7359-2_12","article-title":"Chapter 13: Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases","volume":"75","author":"Tafreshi","year":"2014","journal-title":"Subcell. Biochem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immunotherapy candidate against solid tumors","volume":"139","author":"Tu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/cpt.392","article-title":"CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies","volume":"100","author":"Turtle","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.","volume":"155","author":"Wang","year":"2014","journal-title":"Clin. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-Blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/nejmoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"","journal-title":"Br. J. Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.12602","article-title":"Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: A systematic review of efficacy and safety in clinical trials","volume":"96","author":"Zhu","year":"2015","journal-title":"Eur. J. Haematol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.969020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T06:37:52Z","timestamp":1665383872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.969020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":72,"alternative-id":["10.3389\/fcell.2022.969020"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.969020","relation":{},"ISSN":["2296-634X"],"issn-type":[{"type":"electronic","value":"2296-634X"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"article-number":"969020"}}